6.45

4.59% -0.31

Day One Biopharmaceuticals Inc (DAWN)

Overview News Price History Option Chain Financials Discussions Forecast

Day One Biopharmaceuticals Inc stock is traded at $6.45, with a volume of 1.34M. It is down -4.59% in the last 24 hours and down -11.28% over the past month. Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.

Previous Close:

$6.76

Open:

$6.76

24h Volume:

1.34M

Relative Volume:

1.10

Market Cap:

$803.74M

Revenue:

Net Income/Loss:

$-167.48M

P/E Ratio:

-3.3077

EPS:

-1.95

Net Cash Flow:

$-197.47M

1W Performance:

-18.66%

1M Performance:

-11.28%

6M Performance:

-60.65%

1Y Performance:

-60.62%

1-Day Range:

$6.35

$6.91

1-Week Range:

$6.26

$7.955

52-Week Range:

$6.26

$17.14

Day One Biopharmaceuticals Inc Stock (DAWN) Company Profile

Name

Day One Biopharmaceuticals Inc

Sector

Healthcare (1153)

Industry

Biotechnology (676)

Phone

650 484-0899

Address

2000 SIERRA POINT PARKWAY, SUITE 501, BRISBANE

Employee

181

Twitter

Next Earnings Date

Latest SEC Filings

DAWN's Discussions on Twitter

Compare DAWN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
DAWN Day One Biopharmaceuticals Inc	6.45	803.74M	0	-167.48M	-197.47M	-1.95
VRTX Vertex Pharmaceuticals Inc	424.99	128.84B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	527.78	65.38B	14.09B	4.50B	2.96B	39.28
ARGX Argen X Se Adr	549.65	39.67B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	251.15	33.82B	2.35B	-269.70M	-75.39M	-2.09
ONC Beigene Ltd Adr	231.99	27.60B	3.81B	-644.79M	-669.77M	-6.24

Day One Biopharmaceuticals Inc Stock (DAWN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-09-24	Reiterated	Needham	Buy
Aug-01-24	Upgrade	BofA Securities	Underperform → Buy
Apr-24-24	Reiterated	Needham	Buy
Apr-25-23	Downgrade	BofA Securities	Buy → Underperform
Feb-08-23	Initiated	CapitalOne	Overweight
Feb-03-23	Initiated	Oppenheimer	Perform
Dec-15-22	Initiated	H.C. Wainwright	Buy
Dec-14-22	Initiated	Needham	Buy
Dec-05-22	Initiated	Goldman	Buy
Dec-01-22	Initiated	BofA Securities	Buy

View All

Day One Biopharmaceuticals Inc Stock (DAWN) Latest News

08:13 AM

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Purchased by Dimensional Fund Advisors LP - Defense World

08:13 AM

04:15 AM

Research Analysts Issue Forecasts for DAWN Q2 Earnings - Defense World

04:15 AM

02:37 AM

Needham & Company LLC Cuts Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target to $27.00 - Defense World

02:37 AM

02:09 AM

Research Analysts Set Expectations for DAWN Q2 Earnings - Defense World

02:09 AM

May 09, 2025

Is Day One Biopharmaceuticals, Inc. (DAWN) the Low Risk High Reward Stock Set to Triple by 2030? - Insider Monkey

May 09, 2025

Analysts Issue Forecasts for DAWN Q1 Earnings - Defense World

May 09, 2025

10 Low Risk High Reward Stocks Set to Triple by 2030 - Insider Monkey

May 09, 2025

May 08, 2025

Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Up After Earnings Beat - Defense World

May 08, 2025

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Sold by Mariner LLC - Defense World

May 08, 2025

Day one biopharmaceuticals highlights OJEMDA revenue growth and pipeline progress in Q1 2025 - MSN

May 08, 2025

Day One Biopharmaceuticals (NASDAQ:DAWN) Reaches New 12-Month Low Following Analyst Downgrade - Defense World

May 08, 2025

May 07, 2025

Day One Biopharma’s Earnings Call Highlights Growth - TipRanks

May 07, 2025

Day One Biopharmaceuticals (DAWN) Target Price Adjusted to $26 | DAWN Stock News - GuruFocus

May 07, 2025

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Q1 2025 Earnings Call Transcript - Insider Monkey

May 07, 2025

MetLife Investment Management LLC Raises Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World

May 07, 2025

Day One Biopharmaceuticals earnings beat by $0.07, revenue fell short of estimates - Investing.com Canada

May 07, 2025

Day One Biopharmaceuticals Reports Strong Q1 2025 Results - TipRanks

May 07, 2025